A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Inclusion Criteria: * Adults greater than 18 years of age with documented HIV infection * Highly active antiretroviral therapy (HAART) regimens as defined by the Department of Health and Human Services guidelines; stable regimens for 12 weeks. * CD4 greater than 200 at time of study enrollment * Stable monitoring labs (hematology survey with differential, ALT, creatinine) * Absolute neutrophil count within normal limits Exclusion Criteria: * AIDS defining illness within the last 6 months * Acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections * Women who are pregnant or nursing * Hypersensitivity to etanercept * Previous use of etanercept * Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common skin cancers (non melanoma) * History of active or latent tuberculosis * History of demyelinating nerve disease * History of seizure disorder * Latex allergy * Subject has any of the following laboratory values within 30 days of baseline: * hemoglobin concentration \< 10.0 g/dl for men and \< 9.0 g/dl for women * platelet count \< 75,000/mm3 * AST or ALT \> 5x upper limit of normal (ULN) * serum creatinine \> 2.5x ULN * serum pancreatic amylase \> 1.5 ULN * Subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon * Subjects who chronically use any over-the-counter (OTC) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.